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Monoclonal antibodies against EGFR represent one of the most important recent advance-
ments in the treatment of colorectal cancer. Anyway, to date, only a subset of patients can
really take advantage from this kind of drugs. The identification of predictive factors that
are able to stratify patients who potentially can benefit by these biological treatment, is
an important aim of anticancer research both in clinical and in pre-clinical fields. Many
studies evaluating classical IHC analysis of protein expression failed in this purpose. So
in the last years there was the need to look forward to a new class of molecular predictive
factors. Indeed a number of biomarkers have been evaluated in their potential to predict
the response to anti-EGFR-based therapies. These include marker related to EGFR amplifi-
cation, activation and phosphorylation, EGFR polymorphisms, but also markers related to
Ras/Raf/MAPK and the PI3K/Akt signalling pathways and angiogenesis. This review will
focus the attention to these new genetic and molecular markers.
 2008 Elsevier Ltd. All rights reserved.1. Epidermal growth factor (EGF) pathway
EGFR is a 170 kDa transmembrane glycoprotein composed of
an extracellular ligand-binding domain, a single hydrophobic
transmembrane domain and a cytoplasmic tyrosine kinase-
containing domain.1 It belongs to the ErbB family of tyrosine
kinase receptors that includes four members, namely EGFR,
ErbB-2, ErbB-3 and ErbB-4.2 EGFR is known to homodimerise
or heterodimerise with other ErbB family members, following
the binding to the extracellular domain of the receptor of a set
of specific ligands such as EGF, TGF-a, amphiregulin, betacell-
ulin, heparin-binding EGF and epiregulin.3,4 This dimerisation
leads to auto- and trans-phosphorylation in tyrosine residues
of the ErbB receptors, triggering different intracellular signal-er Ltd. All rights reserved
11206; fax: +39 06
D. Santini).ling cascades including the phosphatidylinositol 3-kinase
(PI3K)/Akt, the ras/raf/MEK/mitogen-activated protein kinase
(MAPK) and the signal transducer and activator of transcrip-
tion (STAT) pathways.5 The final effect of signalling through
EGFR causes a variety of cellular responses, including cell
division, survival, motility, invasion, adhesion and cellular re-
pair.6 Enhanced activity or overexpression of EGFR has been
found to be associated with tumour progression and poor sur-
vival in various malignancies, such as head and neck, lung,
breast, gastrointestinal tract and bladder cancers. In particu-
lar, overexpression of EGFR in colorectal cancer, that occurs in
up to 80% of cases, can be associated to tumour stage and is
able to predict a potential metastatic risk.7–13 Starting from
these evidences, pre-clinical and clinical studies have shown
that targeting EGFR is a valid strategy for anticancer therapy.
Currently, two different treatment strategies for targeting
EGFR and blocking its downstream signalling pathways have
been developed: monoclonal antibodies directed against the.
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tyrosine-kinase activation intracellularly (tyrosine-kinase
inhibitors, TKIs). Anyway, to date, only two EGFR-specific
monoclonal antibodies, cetuximab and panitumumab, have
been approved in Europe and United States for the treatment
of metastatic colorectal cancer patients (CRC).2. EGFR status in immunohistochemistry and
response to EGFR-targeted therapy
The early trials with cetuximab and panitumumab were
based in part on the idea that EGFR status, as determined
by immunohistochemistry, could help enrich or predict for
activity. The data obtained from BOND study showed no cor-
relation between EGFR receptor status and clinical response,
as determined by immunohistochemistry.14
Other published data also suggest that patients not
expressing the EGFR receptor, at least by immunohistochem-
istry, as well as patients who have a high expression of the
receptor can respond.15–17 Similarly other published data, also
for panitumumab, show no difference in activity based on
EGFR staining intensity.18,19
Several biological and technically possible reasonsmay ex-
plain these findings: the expression of EGFR that has been
shown to be very heterogeneous within tumors; the level of
expression can really vary depending upon the specific
immunohistochemistry test used, and finally tissue handling,
processing and storage, which may vary between laborato-
ries, lead to a catalytic degradation of cell surface receptors,
resulting in an altered protein expression.3. EGFR amplification
Moroni and colleagues published interesting data on the pos-
sible predictive role of EGFR gene copy number in the treat-
ment of metastatic colorectal cancer with cetuximab or
panitumumab. EGFR gene amplification evaluated with FISH
correlated with the objective response to treatment, with
eight of nine responders having an increased copy number,
versus only 1 of 21 non-responders.20 Similar results were ob-
tained by Lievre et al. who evaluated EGFR gene amplification
in another series of 30 patients with chromogenic in situ
hybridisation (CISH), showing that all gene-amplified patients
were responders to cetuximab therapy.21 Sartore-Bianchi and
colleagues conducted a retrospective study with the aim to
demonstrate the correlation between the EGFR copy number
and outcomes in patients treated with panitumumab. This
study showed that patients with a high EGFR copy number
or chromosome 7 polysomy-amplification, another marker
of EGFR level, had longer progression-free and overall survival
times when treated with panitumumab.224. EGFR mutations
In the recent past, amongst patients with non-small-cell lung
cancer, a subset of patients have been identified who exhibit
EGFR gene mutations. The presence of these mutations pre-
dicted for the response to EGFR-targeting therapies.23Although these EGFR gene mutations also have been iden-
tified in colorectal cancer, they seem to be very rare and failed
in predicting the response to anti-EGFR treatment.24–26
5. EGFR phosphorylation
To date, a unique and small study conducted by Personeni
et al., suggests that EGFR phosphorylation level might be use-
ful as a biomarker of anti-EGFR therapy efficacy showing a
trend towards higher disease control in patients with high
levels of pEGFR who were treated with cetuximab with or
without irinotecan.27 These preliminary data need further
demonstrations in clinical trials.6. EGFR polymorphisms
The EGFR gene contains a highly polymorphic sequence in in-
tron-1, which consists of a variable number of CA dinucleo-
tide repeats ranging from 9 to 21.28 This sequence has been
shown to affect the efficiency of gene transcription such that
subjects or cell lines with a greater number of CA repeats have
lower levels of mRNA and protein expression.29,30
Graziano et al. demonstrated that, in 110 mCRC patients
treated with cetuximab, EGFR intron-1 S/S polymorphism
(lower number of CA repeat) in germ-line cells was associated
with favourable overall survival and treatment response.31
From a practical perspective, the assessment of the EGFR in-
tron-1 (CA)n could represent an easy and reproducible marker,
and does not change over time. On the other hand, its predic-
tive role might be altered by genetic changes in cancer cells.
7. The Ras/Raf/MAPK and the PI3K/Akt
signalling pathways and related mutations
7.1. KRAS mutation
KRAS, a human homologue of the Kirsten rat sarcoma 2 virus
gene, encodes a signal transducer that operates downstream
of the EGFR so when the KRAS gene is mutated, the KRAS pro-
tein is active regardless of EGFR activation.32
Nowadays, several retrospective studies have clearly sta-
ted the high prognostic and predictive value of KRAS muta-
tions in metastatic CRC patients treated with anti-EGFR
moABs-based therapy.
A small retrospective study conducted by Lievre et al. with
30 cetuximab plus irinotecan refractory patients showed that
40% of the patients had a KRASmutation. On the contrary, pa-
tients with wild-type KRAS had a higher response rate and a
much longer survival than patients with mutated KRAS.33
Moreover, Khambata-Ford demonstrated, in a subsequent
study, that the majority who achieved disease control follow-
ing treatment with cetuximab monotherapy had wild-type
KRAS.34 A study conducted by De Roock et al. in a series of
20 patients with advanced CRC who were randomized to
cetuximab with or without irinotecan showed that KRAS
mutations were inversely correlated with objective responses
to cetuximab and that none of the patients harbouring KRAS
mutation achieved partial response.35 Similarly, Di Fiore
et al. demonstrated in 59 patients with chemotherapy-refrac-
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chemotherapy, that all of the 12 individuals who had objective
clinical responses were of KRAS wild-type.36
A very recently published study including 113 chemore-
fractory colorectal cancer patients treated with cetuximab,
showed a response rate of 30–35% in patients with wild-type
KRAS following treatment with cetuximab plus irinotecan.37
Freeman and colleagues found, in an analysis of 62 tumour
samples from patients treated with panitumumab in 3 phase
II studies and a phase III study, that patients with wild-type
KRAS mutational status are more likely to respond to treat-
ment.38 Amado et al. studied tumour samples from 427 pa-
tients who participated in a randomized phase III trial of
panitumumab versus best supportive care and found an im-
proved progression-free survival over best supportive care in
patients with wild-type KRAS treated with panitunumab.
Interestingly, in patients with mutated KRAS status the treat-
ment with panitumumab was not superior to best supportive
care.39
Given theses results, KRAS mutation status seems to be
the most important candidate to become a standard bio-
marker for predicting response to anti-EGFR-based therapy
in patients with mCRC, but its predictive value has to be con-
firmed by studies prospectively designed to evaluate out-
comes by KRAS status since all data available to date came
from retrospective analyses. Ongoing trials may provide this
answer.40–43
7.2. PTEN status
PTEN is a tumor-suppressor gene located on chromosome 10.
The lipid phosphatase and tensin homologue (PTEN) is a key
tumour suppressor that normally regulates the activation of
PI3K. Deficient PTEN expression leads to the activation of
the phosphoinositide 3-kinase (PI3K)/Akt (pAkt) signalling
pathway.44
Starting from the preclinical evidence that Akt activation
is an important resistance factor for anti-EGFR therapy,45
Frattini et al. conducted a study evaluating PTEN tumour
expression in 27 cetuximab-treated mCRC patients and found
that the patients who achieved a partial response were all
PTEN expressors (10/10).46 Moreover, Loupakis et al. demon-
strated that loss of PTEN expression in colorectal metastasis,
but not in primary tumor, helped in the identification of pa-
tients who cannot benefit from a cetuximab-based therapy.47
7.3. BRAF mutations
BRAF is a serine–threonine-specific protein kinase that is acti-
vated downstream of the small G-protein RAS. BRAF activates
the MAP kinase extracellular signal-regulated kinase (MEK),
which in turn activates the extracellular signal-regulated ki-
nase (ERK). For this reason, BRAF is another candidate bio-
marker for resistance in colorectal cancer, although BRAF
mutations occur in far fewer patients than KRAS mutations.
A recent study by Benvenuti and colleagues suggested that
BRAF status (activation) is associated with the lack of re-
sponse to anti-EGFR mAb treatment in mCRCs patients.48
These preliminary interesting data need further demonstra-
tions in clinical trials.7.4. NF-jB expression
NF-jB (nuclear factor-kappa B) is a protein complex that is a
transcription factor. NF-jB is found in almost all animal cell
types and is involved in cellular responses to stimuli such
as stress, cytokines, growth factors, free radicals, ultraviolet
irradiation, oxidised LDL and bacterial or viral antigen. NF-
jB target genes promote tumour cell proliferation, survival,
migration, inflammation, and angiogenesis. Moreover, NF-jB
is specifically activated by EGFR signalling.49–51
Starting from these evidences, Scartozzi et al. demon-
strated that NF-jB expression evaluated in a series of 76 pa-
tients treated with cetuximab plus cpt 11 for metastatic
colorectal cancer can be predictive of treatment efficacy. In
particular, Scartozzi et al. demonstrated that response rate,
median time to progression and overall survival were signifi-
cantly better in NF-jB-negative patients than in positive
ones.52
7.5. EGFR ligands
The EGF signal pathway is activated by several kinds of stimu-
lations. In particular, elevated expression of epiregulin and/or
amphiregulin may play an important role in tumour growth
and survival by stimulating an autocrine loop through EGFR.
For this reason, Khambata-Ford and colleagues published a
study looking at a possible predictive role of the EGFR ligands
epiregulin and amphiregulin. This author showed that pa-
tients with a high versus low epiregulin expression in meta-
static biopsies have superior progression-free survival rates
and are more likely to have disease control with cetuximab-
based therapies.49 Recently, Yamada et al. found that amphi-
regulin expression in primary lesions of colorectal cancer is
also an important predictive marker of liver metastasis.53
7.6. FccRIIa polymorphism
H/R polymorphism at position 131 of FccRIIIa is associated
with tumour response in follicular lymphoma patients trea-
ted with rituximab as first-line therapy, probably related to a
different induction of an antibody-dependent cellular cyto-
toxicity (ADCC) response induced by the antibody.53 Recently,
Zhang et al. demonstrated that in 39 EGFR-expressing mCRC
patients treated with cetuximab, FccRIIa 131 H/H or H/R geno-
types were associated with a better progression-free survival
compared to patients with R/R genotype, suggesting that
these two polymorphisms could represent useful molecular
markers to predict clinical outcome in this setting of
patients.54
7.7. Angiogenesis and prediction of response
Several mechanisms have been identified in pre-clinical mod-
els whereby cetuximab inhibits the growth and survival of
EGFR-positive tumors. These also include inhibition of angio-
genesis. The mechanisms by which EGFR signalling pathways
regulate VEGF are unclear, but it has been demonstrated that
up-regulation of these factors follows activation of the EGFR
signalling pathways.55 Vincenzi et al. demonstrated that in
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cetuximab plus irinotecan therapy, the modification of circu-
lating level of VEGF during treatment can be predictive of
cetuximab efficacy. Indeed, patients with reduced circulating
levels of VEGF showed a better response rate, a longer median
time to progression and a greater overall survival than those
without them.56–58
8. Conclusions
From these data derives, in the near future, the imperative of
selecting patients who really benefit from anti-EGFR moAbs,
especially those who are potential candidates for secondary
radical liver resection in which the tumour shrinkage is the
major goal of treatment. For these reasons, future perspective
studies may be aimed at evaluating the role of KRAS muta-
tions and the role of other potential candidate molecular pre-
dictive factors in facilitating the choice of which biological
factor (anti-EGFR, anti-VEGF or both) could be the best partner
for up-front chemotherapy.
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